An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204) | Zendy

Jordan Berlin | Zendy; Yang Feng | Zendy; Paul J. Catalano | Zendy; James L. Abbruzzese | Zendy; Philip A. Philip | Zendy; Robert R. McWilliams | Zendy; Andrew M. Lowy | Zendy; Al B. Benson | Zendy; A. William Blackstock | Zendy

Open Access

An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204)

Author(s) -

Jordan Berlin,

Yang Feng,

Paul J. Catalano,

James L. Abbruzzese,

Philip A. Philip,

Robert R. McWilliams,

Andrew M. Lowy,

Al B. Benson,

A. William Blackstock

Publication year - 2017

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000480295

Subject(s) - cetuximab , bevacizumab , medicine , gemcitabine , pancreatic cancer , oncology , chemotherapy , colorectal cancer , gastroenterology , cancer

Evaluate toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely resected pancreatic carcinoma. Secondary objectives included overall survival (OS) and disease-free survival (DFS).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research